Investor Presentaiton
о
☐ An
An Emerging Global Software Company
For personal use only
Citadel Group | Investor Presentation | 2
Global Challenger
Brand in Health
Software
Defensive, recurring
revenue model
Citadel-IXTM Growing
at 66.5%**
Right markets at the
right time
#1 Market Leading products in:
> Pathology, Cancer Care (Aus)
> Radiology and Maternity (UK)
> Successful transformational
acquisition of Wellbeing
Software
> Significant cross sell
opportunities - estimated
market opportunity $250-
$350m total contract value
revenue in tenders over next
2-3 years
$
> Pro forma software revenue
$69.4m, at 65.3% gross profit
margin*
> 77.2% of software revenue is
recurring*
> Defensive business model
with limited impact from
COVID-19
> Proprietary secure Document
Records Management
System (DRMS) platform,
Citadel-IXTM, expanding
rapidly via direct and indirect
channels in Australia and
overseas
> Channel partnership
accelerates growth
opportunities
☑
> Well positioned to capture a
share of expected
digital health spend over the
next 3-5 years due to push for
digitisation, regionalisation
and interoperability
> Pedigree in secure
information management -
well placed to benefit from
regulatory tailwinds
(GDPR, ISO 27001, Data
Privacy, Cyber Security)
*FY20 pro forma
**FY20 actual growth from PCPView entire presentation